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In a recent Nature paper, Itzhaki et al. (2011) generate induced pluripotent stem cells (iPSCs) from patients
with a potentially fatal inherited arrhythmia, long QT syndrome type 2. Cardiomyocytes differentiated from
the patient-derived iPSCs exhibit the hallmark cardiac electrical signatures of the disease, which can be
reversed by pharmacological intervention.The cardiac action potential (AP) is the
electrical signal that triggers contraction
of heart muscle, and it arises due to the
highly orchestrated opening and closing
of dozens of ion channels alongwith contri-
butions from various ion transporters and
exchangers. A rapidly changing balance
of inward and outward ionic currents
through these channels and transporters
produces the prototypical cardiac AP. The
congenital long QT syndrome (LQTS)
occurs when a genetic defect tips the
balance of inward and outward currents to
delay repolarization of the ventricular AP.
The resulting increase in AP duration is re-
flected by a prolongation of the QT interval
on the surface electrocardiogram. The pro-
longed AP can result in early afterdepolari-
zations that under some circumstances
can trigger the potentially fatal ventricular
arrhythmia torsades de pointes. LQTS is
a common cause of sudden cardiac death
in otherwise healthy young adults.
Mutations in at least 12 different ion
channels or channel-associated proteins
have been linked to congenital LQTS.
These mutations can cause gain of func-
tion, which increases depolarizing cur-
rents, or loss of function, leading to re-
duced repolarizing currents. In the case
of LQTS type 2, mutations in the KCNH2
gene encoding the hERG potassium
channel result, via multiple mechanisms,
in reduced rapid delayed rectifier potas-
sium current (IKr) and thus increased AP
duration. In a recent Nature paper, Itzhaki
and colleagues (2011) use a new ap-
proach to study LQTS type 2 using
patient- and disease-specific induced
pluripotent stem cells (iPSCs).130 Cell Stem Cell 8, February 4, 2011 ª2011How do mutations in KCNH2 produce
the disease phenotype? Most of the
understanding of how mutations in ion
channels cause disease is extrapolated
from studies using heterologous expres-
sion systems in which the mutant channel
of interest is expressed in mammalian cell
lines such as immortalized human embry-
onic kidney 293 cells or Xenopus oocytes.
Such studies have provided great insights
into the possiblemechanisms responsible
for the reduction in IKr that causes LQTS
type 2. For example, some mutations of
KCNH2 are associated with abnormal
gating or permeation of the channels,
other mutations impact the biogenesis of
the channels such as trafficking to the
surface membrane, and yet others may
interfere with the biochemical regulation
of the channels (Delisle et al., 2004). One
allele encoding a mutant channel subunit
can act as a dominant-negative sup-
pressor given the tetrameric nature of
the hERG channel. However, the hERG
channel resides in a macromolecular
complex that includes auxiliary subunits
as well as regulatory proteins and poten-
tially other ion channels. Such macromo-
lecular complexes exhibit remarkable
cell-type specificity, and so studying
hERG channels in heterologous systems
may fail to recapitulate their behavior in
the human heart. Mouse models of di-
sease are commonly employed to charac-
terize disease-causing mutations in the
cardiac environment, but in the case of
IKr, this ionic current is essentially absent
in the mouse heart. Patient heart samples
are scarce and not practical for cellular
research studies. Thus, having a modelElsevier Inc.system in which a mutant hERG channel
can be studied in human cardiomyocytes
holds promise to provide new under-
standing of the disease as well as to serve
as a test bed for new therapies.
To generate a human cardiomyocyte
model for LQTS type 2, Itzhaki et al. re-
programmed dermal fibroblasts from
a patient with a missense mutation in the
KCNH2 gene (A614V) using retroviral
vectors for SOX2, KLF4, and OCT4. The
resulting iPSCs were isolated, clonally
expanded, and characterized. After in-
ducing differentiation, both mutant and
control iPSCs gave rise to contracting
embryoid body (EB) outgrowths that in-
cluded cardiomyocytes, based on immu-
nolabeling for cardiac-specific proteins
and gene expression patterns. Isolated
cardiomyocytes were subjected to
patch-clamp recordings of transmem-
brane voltage, and at least three different
types of APs were detected, suggesting
the presence of nodal-like, atrial-like, and
ventricular-like cells, as previously shown
for human iPSC-derived cardiomyocytes
(Zhang et al., 2009). Remarkably, the
ventricular-like andatrial-likeAPdurations
from the LQTS disease cardiomyocytes
were significantly prolonged compared
to control cells. Whole-cell voltage-clamp
studies demonstrated a reduction in the
IKr current in disease cells relative to
control, providing the anticipated cause
for AP prolongation. The reduction in IKr
was more than 50%, consistent with
the dominant-negative effect of this
mutation as suggested byaprior heterolo-
gous expression study of the A614V
mutation (Nakajima et al., 1998). The
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cytes also frequently showed clear proar-
rhythmic electrical activity in the form of
early afterdepolarizations, which can
serve as a trigger for arrhythmias. Thus,
the two major hallmarks for LQTS at the
level of the single cardiomyocyte were
demonstrated in the mutation-carrying
cardiomyocytes: a prolongation of the
AP and the presence of early
afterdepolarizations.
Given the clear disease features of the
LQTS cardiomyocytes, the authors tested
drugs that they predicted may be able to
correct the disease phenotype based
on their modulation of specific ionic
currents involved in repolarization. Three
drugs showed promise in this first screen:
the Ca2+ channel blocker nifedipine, the
KATP channel opener pinacidil, and the
late sodium channel blocker ranolazine.
These candidates represent a first
attempt at testing potentially therapeutic
drugs for LQTS, but as the authors
conclude, careful dose titration would be
needed, as excessive shortening of the
AP duration can also be proarrhythmic.
In addition, the ability to test these drugs
on a particular LQTS mutation cell line
suggests the possibility for personalized
medicine approaches allowing optimiza-
tion of therapies for a given mutation and
genetic background.
The demonstration of a LQTS type 2
model using iPSCs is a significant
advance for a number of reasons. First,
despite multiple theoretical reasons why
this approach should fail, such as the rela-
tive immaturity of the differentiated cardi-
omyocytes, which do not express the
same complement of ion channels as
adult heart, and the heterogeneity of car-
diomyocytes, the study clearly demon-
strates the anticipated changes in AP
duration as well as arrhythmic activity in
the form of early afterdepolarizations.
This study, as well as a recent study of
LQTS type 1, which is due to mutations
in KCNQ1 (Moretti et al., 2010), provide
powerful proof-of-principle demonstra-
tions that iPSCs can serve as an important
model system for investigating inherited
arrhythmia syndromes. Additionally, there
is growing evidence that iPSCs canmodelother forms of inherited heart disease
such as LEOPARD syndrome (Carvajal-
Vergara et al., 2010) and a growing list of
other diseases. Another important ad-
vance provided by Itzhaki et al. is the
demonstration that pharmacological ther-
apies can be tested and developed using
this disease model. This study also
supports the concept that human iPSC-
derived cardiomyocytes can be used to
screen for one of the most common forms
of drug toxicity, drug-induced long QT
syndrome, which is mainly due to the
unintended block of cardiac hERG
channels.
The groundbreaking study by Itzhaki
et al. provides critical proof-of-principle
data demonstrating the promise of iPSC
models for inherited arrhythmias, but
major questions regarding mechanisms
of disease and potential therapies remain
for future investigations. For example,
what was the mechanistic basis for the
decrease in IKr observed?Was this impact
due primarily to altered gating properties
of hERG, as suggested in the heterolo-
gous expression study (Nakajima et al.,
1998), or could abnormalities in protein
biogenesis such as protein trafficking or
degradations play a role? These points
are not simply academic questions,
because the answers will impact potential
therapeutic approaches. In addition, the
as yet unrealized promise of iPSCs for
disease modeling is that this system will
unmask new mechanisms of disease not
readily evident from heterologous expres-
sion systems. For example, how domuta-
tions outside of the coding region of
genes such as in introns lead to disease?
What is the mechanism of variable pene-
trance within family members harboring
the same disease-causing mutation?
How does a mutation in a scaffolding
protein impact multiple associated
proteins present uniquely in native cells?
Clearly, new mechanistic insights into
disease pathology may have implications
for therapy, which makes the patient-
derived disease lines a promising
resource.
Although encouraging observations
were made regarding candidate drug
effects on the cardiac AP in LQTS iPS car-Cell Stem Cell 8diomyocytes, the two most effective
tested drugs, nifedipine and pinacidil,
are unlikely to be clinically relevant given
that the concentrations used by Itzhaki
and colleagues would carry the risk of
unacceptable hypotension due to their
effects on vascular smooth muscle chan-
nels. Sorting out drugs with the needed
specificity to impact heart cells without
adverse effects in other tissues remains
an important challenge. Thus, simply
testing small molecules in the iPSC-
derived cell lineage manifesting the
disease phenotype will only begin the
process.
Future studies will likely benefit from
improved methodologies to differentiate
the iPSCs into the desired cell types,
which will enable potentially more repre-
sentative models such as three-dimen-
sional engineered heart tissue (Eschenha-
gen and Zimmermann, 2005). The LQTS
type 2 iPSCswill be part of a growing tool-
kit of iPSCs used to model various forms
of inherited arrhythmia syndromes and
other human diseases, and it is inevitable
that, as technologies improve in coming
years, many electrifying advances lie
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